Brief: Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial
10/12/2024 11:13
Dec 10 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM
FIRST-LINE
RAS-MUTATED MCRC CLINICAL TRIAL
* CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED AT BOTH
DOSES
* CARDIFF ONCOLOGY INC - ADDITIONAL CLINICAL DATA FROM
CRDF-004
TRIAL EXPECTED IN 1H 2025
Source text: ID:nGNX1fg1Rj
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering